02 February 2012
Signe Sørensen Torekov gave a guest lecture at the International Hospital Diabetes Meeting
Post doc. Signe Sørensen Torekov from the Section of Endocrinology gave the Guest Diabetes Technology Society/EASD Lecture at the International Hospital Diabetes Meeting held in Barcelona, Spain on 17-19 November 2011.
The meeting was held in collaboration with the European Association for the Study of Diabetes (EASD).
The topic of the lecture was "GLP-1 as a therapy, beyond lowering glucose", with focus of the role of GLP-1 agents in new areas including for the management of obesity and cardiovascular disease.
Preclinical studies suggest that the incretin hormone GLP-1 may have cardioprotective effects and clinical studies suggest GLP-1 may improve cardiovascular function. The blood pressure is modestly reduced and lipid profiles are modestly improved by incretin therapies. Incretin mimetics induce weight loss which may reduce cardiovascular events.
In the clinical trials with GLP-1 based agents, the overall incidence of cardiovascular events is numerically lower. Thus, results are encouraging, but we need data from long-term cardiovascular outcomes trials. In summary, GLP-1-based therapies have the potential to improve cardiovascular outcomes in type 2 diabetes.
The aim of the Diabetes Technology Society (www.journalofdst.org) is to bring together academics, health-care professionals, scientists, administrators and industry to discuss the delivery of health care for people with diabetes admitted to the hospital.